GO BEYOND BINARY READOUT IN DRUG DEVELOPMENT
Artificial Intelligence and Precision Medicine design leading to accelerated drug development and expedited regulatory approval
Artificial Intelligence and Precision Medicine design leading to accelerated drug development and expedited regulatory approval
Using our pioneering eXplainable AI platform KEM® we design and execute Precision Medicine clinical trials, with an unparalleled successful track record across multiple therapeutic areas. Thanks to our XAI KEM® platform we integrate extensive pre-clinical, clinical as well as Real World Evidence data, to define best dose, identify patient selection and surrogate endpoint biomarkers as well as alternative clinical indications. Our Precision Medicine clinical protocols allow for extensive data collection and use of stratification biomarkers, enabling accelerated approval regulatory pathways.
Our technology matches all steps of clinical development and can be used even with small datasets of 10-20 patients.
KEM®, Ariana’s AI platform, is able to test billions of hypotheses to identify the best patient responders for a clinical trial. It helps reduce trial heterogeneity and accelerates the development of new medicines.
Collaboration connects CorpusAnalytiX’s diverse healthcare data mark...
It is with profound sadness that we announce the passing of our founde...
Cast your mind back to when Ariana was founded… Facebook was jus...
Artificial Intelligence and organoid data to accelerate the developmen...